

SpikImm Appoints Bruno Lucidi to Its Board of Directors

Paris, France – June 1st, 2026 – SpikImm, a clinical-stage biotechnology company specializing in the development of high-affinity monoclonal antibodies, using advanced molecular biology and artificial intelligence, against viral infections, today announced the appointment of Bruno Lucidi to its Board of Directors, effective June 1st, 2026.

Bruno Lucidi is an international leader with extensive transversal experience from drug discovery to market and in global corporate strategy within the biopharmaceutical industry. Over the course of his career, he has defined and executed global strategies for leading organizations such as Bristol Myers Squibb, Johnson & Johnson, and GlaxoSmithKline.

His previous roles include founding Chief Executive Officer of Mink Therapeutics (NASDAQ:INKT) in the United States, UK, Hong Kong and Belgium, CEO of Karolinska Development, an evergreen found publicly traded, CEO of Aprea, and Akinion in Sweden; Vice President at GSK head of the pediatric franchise with teams in Belgium, London and Singapore; Worldwide Vice President of Virology & Oncology at Johnson & Johnson; Chairman of the Board of Pharmasset; and founding Chief Executive Officer of Idenix Pharmaceuticals in the USA.

In addition, Bruno Lucidi served as a Life Sciences Expert at the Wallonia Export & Investment Agency (AWEX) in charge of foreign investment for the government agency in Belgium, and expert for the European Commission. He is currently Board Director at Atea Pharmaceuticals, and a Senior advisor to several biopharmaceutical companies and investors.

“We are delighted to welcome Bruno Lucidi to our Board. His extensive expertise in infectious diseases, Immunology and Oncology and his proven track record in leading successful biotechnology companies will be invaluable as we continue to develop SpikImm as a key player in the space of monoclonal antibodies against viral infections, including anti-BK virus and prospective pandemic viruses” said Philippe Pouletty, M.D., cofounder of Truffle Capital, founder and chairman of SpikImm.

“I am excited to join SpikImm at such an important stage of its development. The company’s expertise in selecting and engineering monoclonal antibodies to prevent and treat viral infections and its strong potential to address unserved indications such as BK virus reactivation in transplant patients, make this a compelling opportunity. I look forward to contributing to its growth and success.” said Bruno Lucidi.

About SpikImm

SpikImm is a clinical-stage biotechnology company, founded by Truffle Capital (the founder of Abivax), in collaboration with Institut Pasteur, and supported by Bpifrance, dedicated to the discovery and development of next-generation monoclonal antibodies targeting viruses. Leveraging a proprietary platform developed in collaboration with several prestigious academic and clinical centers, SpikImm aims to deliver rapid, effective, prophylactic, and therapeutic solutions to address current and future viral threats.